Depemokimab: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 11, 2026🚩 Report this page

Depemokimab

Other Systemic Drugs For Obstructive Airway Diseases

Sold as Exdensur

GB MHRAEU EMA

Drug class: Other Systemic Drugs For Obstructive Airway Diseases
Availability: See label
Markets covered: 2
Products on record: 3

R03DXOther Systemic Drugs For Obstructive Airway Diseases

Overview

Depemokimab is an active pharmaceutical ingredient in the Other Systemic Drugs For Obstructive Airway Diseases group (R03DX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	2	December 19, 2025
EU European Union	EMA	1	May 11, 2026

GBUnited Kingdom· MHRA

2 products

Uses

GBOfficial regulatory label· revised December 19, 2025[1]

Asthma EXDENSUR is indicated as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on maximum moderate- dose or high-dose inhaled corticosteroids (ICS) plus another asthma controller.
Chronic rhinosinusitis with nasal polyps (CRSwNP) EXDENSUR is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.

How to take

EUEuropean Union· EMA

1 product

Uses

EUOfficial regulatory label· revised May 11, 2026[2]

1). Chronic rhinosinusitis with nasal polyps (CRSwNP) EXDENSUR is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

How to take

Sources & citations

[1]MHRA (UK) · PL194940328 · revised December 19, 2025
[2]European Medicines Agency · EMEA/H/C/006446 · revised May 11, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised December 19, 2025[1]

Summary of the safety profile The most common adverse reactions reported with depemokimab were local injection site reactions (2%). Tabulated list of adverse reactions The safety of depemokimab was studied in a clinical development programme in adult and adolescent patients aged 12 years and older with asthma (SWIFT-1 and SWIFT-2 studies) and in adult patients with CRSwNP (ANCHOR-1 and ANCHOR-2 studies).
In these 4 randomised, 52-week, placebo-controlled, multicentre studies, patients received either subcutaneous (SC) depemokimab or placebo once every 6 months. A total of 773 patients received at least one dose of depemokimab 100 mg in these studies.
Other phase 3 clinical studies include an open-label 52-week extension study (AGILE) involving asthma patients (n = 629) who had previously completed either of the two asthma studies (SWIFT-1 or SWIFT-2), and an ongoing 52-week study (NIMBLE) involving asthma patients who were previously treated with other anti- IL5/IL-5R biological medicines prior to study entry (n = 538).
Adverse reactions associated with depemokimab are presented in the table below (Table 1). Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000) and very rare (< 1/10 000).
Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness. Table 1. Adverse reactions System Organ Class Adverse reactions Frequency Immune system disorders Hypersensitivity reactions (systemic allergic)a b Uncommon Skin and subcutaneous tissue disorders Pruritus Common General disorders and administration site conditions Administration-related systemic reactions (non- allergic)b c Local injection site reactionsd Common a Observed in a phase 1 study and in an open-label extension study b The majority of events (85%) resolved in ≤7 days, with most events (65%) resolving in ≤2 days from their onset.
c Symptoms include headache, fatigue, rash. d Symptoms include pain, erythema, swelling, and itching. The majority of events were mild in intensity and 79% resolved in ≤7 days, with most events (56%) resolving in ≤2 days from their onset.
Paediatric population A total of fifteen adolescents (aged 12-17) received depemokimab in two placebo- controlled studies for asthma (SWIFT-1 and SWIFT-2) of 52 weeks duration. The safety profile was generally similar to that seen in adults.
No additional adverse reactions were identified. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised December 19, 2025[1]

Traceability In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Hypersensitivity reactions Acute and delayed systemic reactions, including hypersensitivity reactions (such as urticaria and pruritus), have occurred following administration of depemokimab.
, days). In the event of a hypersensitivity reaction, appropriate treatment should be initiated and clinical judgement must be used regarding re- administration of depemokimab. Asthma-related adverse events or exacerbations Depemokimab must not be used to treat acute asthma symptoms or acute exacerbations.
Asthma-related adverse events or exacerbations may occur during treatment with depemokimab. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with depemokimab.
Reduction of corticosteroid dosage Abrupt discontinuation of background medications (including systemic and inhaled corticosteroids) after initiation of depemokimab therapy is not recommended. Reductions in the dosages of background medications, if appropriate, must be gradual and performed under the supervision of a physician.
Parasitic (helminth) infections Eosinophils may be involved in the immunological response to some helminth infections. Patients with pre-existing helminth infections were excluded from participation in the clinical programme. Patients with pre-existing helminth infections should be treated for their infection prior to depemokimab therapy.
If patients become infected while receiving treatment with depemokimab and do not respond to anti- helminth treatment, consider delaying administration of the next depemokimab dose until the infection resolves. Excipients This medicinal product contains polysorbate 80 (see section 2), which may cause allergic reactions.
This medicinal product contains less than 1 mmol sodium (23 mg) per 100 mg dose, that is to say essentially “sodium-free”.

This is not medical advice. Consult a qualified healthcare professional.